Non-invasive intraventricular pressure differences estimated with cardiac MRI in subjects without heart failure and with heart failure with reduced and preserved ejection fraction by Londoño Hoyos, Francisco Javier et al.
Open access 
  1Londono-Hoyos F, et al. Open Heart 2019;6:e001088. doi:10.1136/openhrt-2019-001088
To cite: Londono-Hoyos F, 
Segers P, Hashmath Z, et al. 
Non-invasive intraventricular 
pressure differences estimated 
with cardiac MRI in subjects 
without heart failure and with 
heart failure with reduced and 
preserved ejection fraction. 
Open Heart 2019;6:e001088. 
doi:10.1136/
openhrt-2019-001088
Received 13 May 2019
Revised 24 June 2019
Accepted 11 September 2019
1Hospital of the University of 
Pennsylvania and University 
of Pennsylvania, Philadelphia, 
Pennsylvania, USA
2Institute Biomedical Technology 
(IBiTech) - bioMMeda Research 
Group, Ghent University, Gent, 
Belgium
3Corporal Michael J. 
Crescenz VAMC, Philadelphia, 
Pennsylvania, USA
Correspondence to
Dr Julio Alonso Chirinos;  julio. 
chirinos@ uphs. upenn. edu
Non-invasive intraventricular pressure 
differences estimated with cardiac MRI 
in subjects without heart failure and 
with heart failure with reduced and 
preserved ejection fraction
Francisco Londono-Hoyos,1,2 Patrick Segers,2 Zeba Hashmath,1 Garrett Oldland,1,3 
Maheshwara Reddy Koppula,1 Khuzaima Javaid,3 Rachana Miller,1,3 
Rushikkumar Bhuva,1,3 Izzah Vasim,1,3 Ali Tariq,3 Walter Witschey,1 Scott Akers,3 
Julio Alonso Chirinos  1,2,3
Heart failure and cardiomyopathies
© Author(s) (or their 
employer(s)) 2019. Re-use 
permitted under CC BY-NC. No 
commercial re-use. See rights 
and permissions. Published 
by BMJ.
Key questions
What is already known about this subject?
 ► Both systolic and diastolic dysfunction are present 
in heart failure (HF) with reduced (HFrEF) and with 
preserved ejection fraction (HFpEF). Thus, a better 
understanding of the nature of physiological abnor-
malities in subjects with HF is essential to improve 
its management. Non-invasive quantitative analysis 
of intraventricular flow dynamics, such as blood 
flow velocities, provide important insights into the 
processes driving left ventricular (LV) ejection and 
filling. The spatiotemporal pattern of LV blood flow 
velocities can provide additional information from 
estimations of underlying intraventricular pressure 
differences (IVPDs) driving diastolic and systolic in-
traventricular flow in HFrEF and HFpEF.
What does this study add?
 ► Our study demonstrated the feasibility to as-
sess IVPDs throughout the cardiac cycle using 
phase-contrast MRI and comparing IVPDs between 
subjects without HF and subjects with HFrEF and 
HFpEF. The proposed MRI-based method is more 
flexible in terms of the definition and alignment of 
the operator’s ‘scan line’, and thus in the potential 
analysis conducted, than the echocardiographic 
standard approach and could be performed com-
plementary to routine MRI protocols. Furthermore, 
our findings suggest distinct patterns of systolic and 
diastolic IVPDs in HFpEF and HFrEF, implying differ-
ences in the nature of diastolic dysfunction between 
the HF subtypes.
How might this impact on clinical practice?
 ► Further research is warranted to exploit MRI anal-
ysis thoroughly to assess the significance of these 
novel indices regarding risk stratification and re-
sponse to therapy.
ABSTRACT
Objective Non-invasive assessment of left ventricular 
(LV) diastolic and systolic function is important to better 
understand physiological abnormalities in heart failure (HF). 
The spatiotemporal pattern of LV blood flow velocities during 
systole and diastole can be used to estimate intraventricular 
pressure differences (IVPDs). We aimed to demonstrate the 
feasibility of an MRI-based method to calculate systolic and 
diastolic IVPDs in subjects without heart failure (No-HF), and 
with HF with reduced ejection fraction (HFrEF) and HF with 
preserved ejection fraction (HFpEF).
Methods We studied 159 subjects without HF, 47 
subjects with HFrEF and 32 subjects with HFpEF. Diastolic 
and systolic intraventricular flow was measured using 
two-dimensional in-plane phase-contrast MRI. The Euler 
equation was solved to compute IVPDs in diastole (mitral 
base to apex) and systole (apex to LV outflow tract).
Results Subjects with HFpEF demonstrated a higher 
magnitude of the early diastolic reversal of IVPDs 
(−1.30 mm Hg) compared with the No-HF group 
(−0.78 mm Hg) and the HFrEF group (−0.75 mm 
Hg; analysis of variance p=0.01). These differences 
persisted after adjustment for clinical variables, Doppler-
echocardiographic parameters of diastolic filling and 
measures of LV structure (No-HF=−0.72; HFrEF=−0.87; 
HFpEF=−1.52 mm Hg; p=0.006). No significant differences 
in systolic IVPDs were found in adjusted models. IVPD 
parameters demonstrated only weak correlations with 
standard Doppler-echocardiographic parameters.
Conclusions Our findings suggest distinct patterns of 
systolic and diastolic IVPDs in HFpEF and HFrEF, implying 
differences in the nature of diastolic dysfunction between 
the HF subtypes.
IntROduCtIOn
The incidence and prevalence of heart failure 
(HF) is increasing worldwide.1 Clinically, 
two major subtypes of HF are identified2–4 
based on the left ventricular (LV) ejection 
fraction (EF): HF with reduced (HFrEF) and 
with preserved EF (HFpEF).2–4 Although 
LV systolic dysfunction is thought to be the 
G
eneeskunde - P8 / 1e Verd. Protected by copyright.
 o
n
 D
ecem
ber 24, 2019 at Biom
edische Bibliotheek Fac
http://openheart.bmj.com/
O
pen Heart: first published as 10.1136/openhrt-2019-001088 on 9 O
ctober 2019. Downloaded from
 
Open Heart
2 Londono-Hoyos F, et al. Open Heart 2019;6:e001088. doi:10.1136/openhrt-2019-001088
key pathophysiological abnormality in HFrEF, diastolic 
dysfunction is also present in this condition. Similarly, 
whereas diastolic dysfunction is thought to be a key patho-
physiological abnormality in HFpEF, systolic contractile 
abnormalities have been also reported in this condition. 
Therefore, a better understanding of the nature of physi-
ological abnormalities in HF patients is desirable.
Non-invasive quantitative analysis of intraventricular 
flow dynamics can provide important insights into the 
processes driving LV ejection and filling. While the anal-
ysis of blood flow velocities (in particular, the transmi-
tral flow velocities) is extensively used in the evaluation 
of LV function,5–7 much less is known about underlying 
pressure differences driving diastolic and systolic intra-
ventricular flow in HFrEF and HFpEF. These pressure 
differences can be inferred by solving the Euler equa-
tion, a simplified version of the Navier-Stokes equa-
tions,8 9 using information regarding the spatiotemporal 
pattern of LV blood flow velocities, which in turn can be 
obtained using ultrasound (eg, colour M-mode record-
ings along a transmitral scanline) or MRI. The computa-
tion of intraventricular pressure differences (IVPDs) has 
been applied in the context of diastolic function analysis 
but can also be applied to systole, to interrogate pressure 
gradients produced by LV ejection.
The aim of this study is to demonstrate the feasibility of 
an MRI-based method to characterise IVPDs throughout 
diastole and systole.
MetHOds
We prospectively enrolled a sample of patients at the 
Corporal Michael J. Crescenz VA Medical Center. The 
protocol was approved by the Philadelphia VA Medical 
Center Institutional Review Board, and all subjects 
provided written informed consent.
HFrEF was defined as a symptomatic HF in the pres-
ence of a left ventricular ejection fraction (LVEF) <50%. 
HFpEF was defined as the presence of all of the following: 
(1) New York Heart Association (NYHA) Class II–IV symp-
toms consistent with HF; (2) LV ejection fraction >50%; 
(3) Mitral inflow early diastolic (E wave) to annular tissue 
velocity (e’) ratio >14,10 or at least two of the following: (a) 
an average mitral E/e’ ratio >8; (b) treatment with a loop 
diuretic for control of HF symptoms; (c) left atrial volume 
index >34 mL/m2 of body surface area; (d) NT-pro B-type 
natriuretic peptide level >200 pg/mL; (e) LV mass index 
>149 g/m2 in men and 122 g/m2 in women (measured by 
cardiac MRI).11 No-HF subjects had an LVEF >50%, no 
significant valvular disease, and no symptoms and signs 
consistent with HF.12
Key exclusion criteria were: (1) claustrophobia; (2) 
presence of metallic objects or implanted medical devices 
in body; (3) more than mild aortic stenosis; (4) atrial 
fibrillation; (5) conditions that would make the study 
measurements less accurate or unreliable (ie, arrhythmia 
affecting cardiac gating, inability to perform an adequate 
breath hold for cardiac MRI acquisitions); (6) known 
infiltrative or hypertrophic cardiomyopathy, or extracar-
diac amyloidosis or sarcoidosis.12
doppler echocardiography
Doppler transthoracic echocardiography was performed 
at rest with the patient in supine position using a Vivid E9 
device (GE Healthcare, Horten, Norway), equipped with 
a cardiac probe.
two-dimensional phase contrast imaging acquisition and 
processing
Intraventricular flow velocities were measured with 
phase-contrast MRI, using a 1.5T MRI scanner (Avanto 
system; Siemens Healthcare; Erlangen, Germany). A 
phase contrast gradient echo pulse sequence with in-plane 
velocity encoding was applied using retrospective gating 
in a plane corresponding to the three-chamber view (‘LV 
outflow tract view’) in which both the mitral inflow and 
the LV outflow are well visualised. We performed two 
consecutive breath-held acquisitions, each with in-plane 
velocity encoding in one direction. Both acquisitions 
were merged offline to obtain the in-plane two-dimen-
sional-velocity maps. Images were obtained with the 
following imaging parameters: TE=2.7 ms, TR=4.8 ms, 
temporal resolution=39.8 ms, bandwidth=450 Hz/pixel, 
field-of-view=360×360 mm2, matrix=152–192×256, spatial 
resolution=1.88×1.88 mm2, slice thickness=6 mm, flip 
angle=20°. Maximal velocity encoding was usually set at 
130 cm/s but adjusted during the examination to avoid 
aliased velocity measurements.
Image processing and computation of IVPds
A MATLAB (MathWorks, Natick, Massachusetts, USA) 
custom-designed graphic user interface was programmed 
to process all phase-contrast MRI sequences. The pres-
sure difference between two points in a plane (the scan-
ning plane) can be calculated from the two-dimensional 
planar velocity information as13
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with pressure derivatives linked through the Euler 
equation to the two-dimensional-velocity information:
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with  u the two-dimensional-component vector (ux, uy) 
of local blood velocity and  ρ , blood density (1060 Kg/m
3).
The instantaneous pressure difference between any two 
points along this streamline  
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change in velocity with time at a given spatial point (iner-
tial component, 
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), and the change in velocity with 
space at any given time (convective component,  
(
u∂u∂s
)
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8
For the assessment of diastolic IVPDs, 2–4 reference 
points were placed inside the LV along the inflow direc-
tion at the mitral annulus (Point 1, P1) and the LV 
apex (Point 2, P2) (figure 1A, B). For the assessment 
of systolic IVPDs, 2–4 reference points were placed 
along the outflow direction, from the LV apex (P1) to 
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Figure 1 Graphical description of the phase-contrast 
MRI sequence processing to assess diastolic function (left 
column) and systolic function (right column). (A) and (E) 
original magnitude images and (B) and (F) calculated velocity 
vectors images, showing the reference points selection, 
located at: (left) the mitral annulus (P1) and LV apex (P2); 
and (right) LV apex (P1) and aortic annulus (P2). (C) and (G) 
the pseudo colour M-mode image, calculated from the two-
dimensional velocity vectors, was used as quality reference 
of the IVPD curves. Calculated IVPD curves (solid black 
line): (D) during diastole, showing the (1) E-wave (E-IVPD), (2) 
reversal E-wave (ER-IVPD) and (3) A-wave (A-IVPD) pressure 
peaks, and (H) during systole, showing the (1) S-wave 
(S-IVPD) and (2) reversal S-wave (SR-IVPD) pressure peaks. 
(C, D) and (G, H) are aligned in time, respectively. Important 
to REMARK, the colour scale in (B, C, F) and (G) is a visual 
guidance for the user during the processing, and the linear 
(two points) and the curvilinear (four points) approximation 
could be selected by the user for diastolic and/or systolic 
analysis. IVPD, intraventricular pressure difference.
the aortic annulus (P2) (figure 1E, F). To note, points 
were: (1) placed using the frame with the best anatom-
ical view of the structures and (2) stationary through the 
whole cardiac cycle. A pseudo-colour M-mode image was 
calculated projecting velocity components within the 
path delimited by the reference points and displayed for 
processing visual guidance (figure 1C, G).
Available velocity components were used to calculate 
pressure gradient fields and differences. Then, interpo-
lated values along the line delimited by P1 and P2 were 
used to solve equation 1, applying a direct integration 
method13 to obtain the IVPD curves (figure 1D, H).
statistical analysis
Descriptive data are presented as mean±SD or mean 
(95% CI) for continuous variables or counts (%) for 
categorical variables. Differences between groups were 
determined by one-way analysis of variance (ANOVA) 
and adjusted for potential confounders. Physiological 
indices were expressed as absolute values as well as abso-
lute differences between measurements (with 95% CIs). 
A p value <0.05 was considered statistically significant. 
We presented a model with unadjusted data, and three 
adjusted models: model 1—adjusted for clinical data 
(age, sex, African American ethnicity, body mass index 
(BMI), coronary artery disease, estimated glomerular 
filtration rate (eGFR) and beta-blocker, ACE-Inhibi-
tor/angiotensin receptor blocker (ARB), loop diuretic 
and spironolactone use); model 2—model 1 addi-
tionally adjusted for echo parameters (Mitral E-wave 
velocity, E-wave deceleration time, Mitral annular e’ 
septal); model 3—model 2 additionally adjusted for 
MRI data (LV mass index and end-diastolic volume 
index (EDVI)). Statistical analyses were performed 
using MATLAB statistics and machine learning toolbox 
(Matlab 2016b, the Mathworks; Natwick, Massachusetts, 
USA) and SPSS for Mac V.22.
Reproducibility and repeatability assessment
To test the method’s reproducibility (measurements 
performed by two different operators at least 1 year apart) 
and repeatability (measurements performed by the same 
operator at least 1 week apart), 10 cases (included in 
the study) were assessed, calculating the Pearson r-value 
squared (r2), the sum of squared error (SSE) and the 
reproducibility coefficient (RPC).
echocardiographic/MRI correlation assessment
To evaluate the potential added value of the proposed 
technique, correlation coefficients were calculated 
between selected MRI parameters and established 
Doppler-echocardiographic indices of diastolic function.
Results
General characteristics of the study population are shown 
in table 1. The mean age of participants with HFrEF, 
HFpEF and without HF was 65.9, 62.9 and 61.8 years, 
respectively. The HFrEF group demonstrated a high prev-
alence of hypertension, diabetes, coronary artery disease 
and pronounced left atrial enlargement. Consistent with 
the HFpEF phenotype, subjects in this group were obese 
and had a high prevalence of hypertension and diabetes. 
Most subjects with HFrEF and HFpEF were receiving beta 
blockers, an ACE inhibitor or ARB, and loop diuretics. 
The study sample was composed predominantly of males, 
with a high proportion of African-Americans, particularly 
in the HFrEF group.
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Table 1 General characteristics of study subjects
Variable
No-HF
(n=159)
HFrEF
(n=47)
HFpEF
(n=32) P value
Age (years) 61.8±11.5 65.9±10.7 62.9±8.6 0.09
Male 145 (91) 46 (98) 28 (88) 0.18
Race       
  African-American 72 (45) 31 (66) 16 (50) 0.04*
  Caucasian 74 (47) 15 (32) 15 (47) 0.20
BMI (kg/m2) 29.5 (25.7, 33.1) 27.9 (24.2, 32.9) 35 (29.3, 41.7) 0.0007†‡
Heart rate (bpm) 68.9±13 69±11.9 67.4±11.9 0.84
Ejection duration (ms) 319±30 311±47 325±33 0.27
Current smoker 43 (28) 15 (33) 8 (25) 0.73
Hypertension 118 (75) 41 (89) 29 (91) 0.03
Diabetes 64 (41) 27 (59) 18 (56) 0.04*
Coronary artery disease 47 (30) 24 (51) 11 (34) 0.03*
Drug therapy       
Beta blocker 74 (47) 43 (91) 24 (75) <0.0001*†
  ACE-inhibitor/ARB 80 (51) 37 (79) 26 (81) <0.0001*†
  Calcium-channel
  blocker
41 (26) 12 (26) 13 (41) 0.23
  Spironolactone 3 (2) 6 (13) 4 (13) 0.002*†
  Statin 103 (65) 36 (77) 21 (66) 0.33
  Aspirin 84 (53) 37 (79) 19 (59) 0.007*
  Thiazide 34 (22) 11 (23) 5 (16) 0.74
  Loop diuretics 2 (1) 35 (74) 23 (72) <0.0001*†
eGFR (mL/min/1.73 m2)§ 86 (65, 99.8) 74 (56.5, 92.3) 84 (63, 99) 0.056*
LV EF (%) 59.6 (52.2, 65.6) 36.6 (23.7, 42.5) 61.4 (58, 70.3) <0.0001*‡
LA volume index (mL/m2) 30.7 (23.8, 39.5) 46.1 (35.7, 65.3) 36.6 (26.4, 49.9) <0.0001*
LV EDVI (mL/m2) 69.9 (58.4, 82.4) 102.7 (85.8, 141.4) 69.1 (56.7, 79.5) <0.0001*‡
LV mass index BSA (g/m2) 64.5 (56.9, 76.5) 88.6 (77.9, 107.1) 72 (59.3, 83.2) <0.0001*‡
Mitral E-wave velocity (cm/s) 69.5 (58.1, 85.5) 74.3 (54.7, 93.6) 69.6 (60.5, 92.7) 0.54
Mitral E-wave deceleration time (ms) 210 (170, 240) 180 (140, 220) 220 (170, 270) 0.06
Mitral A-wave velocity (cm/s) 74.6±21.7 62.3±22.3 74.7±19.6 0.008*
Mitral annular e’, septal (cm/s) 7.58 (5.9, 9.65) 5.61 (4.12, 7.9) 6.77 (5.24, 8.19) 0.0007*
Values are mean±SD or mean (95% CI), or counts (percentages).
*p<0.05 for No-HF vs HFrEF.
†p<0.05 for No-HF vs HFpEF.
‡p<0.05 for HFrEF vs HFpEF.
§eGFR was calculated using the Modification of Diet in Renal Disease Study equation.
ACE, angiotensin convertase enzyme; ARB, angiotensin receptor blocker; BSA, body surface area; EF, ejection fraction; eGFR, estimated 
glomerular filtration rate; HFpEF, HF with preserved ejection fraction; HFrEF, HF with reduced ejection fraction; LV, left ventricular.
In all three groups (No-HF, HFrEF and HFpEF), subjects 
exhibited, in general, consistent IVPD patterns described 
previously using colour M-mode Doppler echocardiog-
raphy14–17 or cardiac MRI13 18 19 (figure 1D, H). The diastolic 
period of the calculated IVPD waveforms was typically 
characterised by (1) a large early diastolic forward positive 
difference (E-IVPD) during ventricular relaxation, associ-
ated with early diastolic rapid filling; (2) an early diastolic 
negative peak associated with the deceleration of the early 
filling (ER-IVPD); (3) a second, late diastolic, positive peak 
(A-IVPD) associated with atrial contraction (see figure 1D). 
The systolic period was characterised by a typical biphasic 
configuration with (1) a large forward positive peak 
(S-IVPD) associated with ventricular systole (rapid ejec-
tion) followed by (2) a negative peak (SR-IVPD) associated 
with its deceleration (slow ejection phase) (see figure 1H). 
Selected IVPD parameters are shown and compared in 
table 2, and figures 2 and 3.
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Table 2 Comparison of diastolic and systolic intraventricular pressure difference parameters between the groups
Variable
No-HF
(n=159)
HFrEF
(n=47)
HFpEF
(n=32) P value
Unadjusted model
E-IVPD (mm Hg) 0.76 (0.68, 0.84) 0.83 (0.67, 0.98) 0.83 (0.64, 1.02) 0.63
ER-IVPD (mm Hg) −0.78 (−0.93, −0.63) −0.75 (−1.02, −0.47) −1.30 (−1.60, −0.99) 0.01*†
A-IVPD (mm Hg) 0.93 (0.85, 1.02) 0.72 (0.56, 0.88) 0.92 (0.73, 1.11) 0.07
S-IVPD (mm Hg) 1.7 (1.56, 1.84) 1.41 (1.16, 1.65) 1.99 (1.65, 2.34) 0.01†
SR-IVPD (mm Hg) −1.15 (−1.28, −1.02) −0.90 (−1.17, −0.64) −1.37 (−1.64, −1.10) 0.04†
Adjusted model 1
E-IVPD (mm Hg) 0.75 (0.65, 0.85) 0.86 (0.64, 1.08) 0.85 (0.61, 1.08) 0.70
ER-IVPD (mm Hg) −0.76 (−0.95, −0.56) −0.85 (−1.23, −0.47) −1.35 (−1.72, −0.97) 0.02*
A-IVPD (mm Hg) 0.94 (0.83, 1.05) 0.71 (0.49, 0.92) 0.94 (0.70, 1.17) 0.15
S-IVPD (mm Hg) 1.7 (1.52, 1.89) 1.49 (1.14, 1.84) 1.89 (1.47, 2.3) 0.16
SR-IVPD (mm Hg) −1.15 (−1.32, −0.98) −0.94 (−1.30, −0.58) −1.34 (−1.67, −1) 0.14
Adjusted model 2
E-IVPD (mm Hg) 0.84 (0.71, 0.97) 0.93 (0.67, 1.19) 0.79 (0.54, 1.04) 0.62
ER-IVPD (mm Hg) −0.68 (−0.92, −0.45) −0.99 (−1.41, −0.56) −1.48 (−1.87, −1.08) 0.009*
A-IVPD (mm Hg) 0.97 (0.84, 1.11) 0.75 (0.50, 1.00) 0.97 (0.72, 1.22) 0.27
S-IVPD (mm Hg) 1.72 (1.49, 1.96) 1.46 (1.03, 1.89) 1.86 (1.39, 2.33) 0.25
SR-IVPD (mm Hg) −1.17 (−1.34, −0.99) −0.83 (−1.21, −0.46) −1.32 (−1.64, −1.01) 0.04†
Adjusted model 3
E-IVPD (mm Hg) 0.85 (0.72, 0.99) 0.91 (0.63, 1.20) 0.79 (0.54, 1.05) 0.76
ER-IVPD (mm Hg) −0.72 (−0.96, −0.49) −0.87 (−1.34, −0.40) −1.52 (−1.92, −1.13) 0.006*†
A-IVPD (mm Hg) 0.98 (0.85, 1.12) 0.73 (0.46, 1.00) 0.99 (0.73, 1.24) 0.24
S-IVPD (mm Hg) 1.74 (1.5, 1.98) 1.47 (1.01, 1.92) 1.86 (1.37, 2.34) 0.34
SR-IVPD (mm Hg) −1.17 (−1.35, −0.99) −0.86 (−1.25, −0.47) −1.31 (−1.64, −0.99) 0.11
Data are presented as mean (95% CI).
Unadjusted model; adjusted model 1: adjusted for clinical data (age, sex, African American ethnicity, BMI, coronary artery disease, eGFR 
and beta blocker, ACE-inhibitor, ARB, loop diuretic, and spironolactone use); adjusted model 2: model 1 additionally adjusted for echo 
parameters (Mitral E-wave velocity, E wave deceleration time, Mitral annular e’ septal); adjusted model 3: model 2 additionally adjusted for 
MRI data (LV mass index and EDVI).
*p<0.05 for No-HF vs HFpEF.
†p<0.05 for HFrEF vs HFpEF.
‡p<0.05 for No-HF vs HFrEF.
EDVI, end-diastolic volumen index; eGFR, estimated glomerular filtration rate; HF, heart failure; HFpEF, HF with preserved ejection fraction; 
HFrEF, HF with reduced ejection fraction; IVPD, intraventricular pressure difference; LV, left ventricular.
diastolic IVPds
Unadjusted comparisons demonstrated no signifi-
cant differences in E-IVPD (No-HF=0.76; HFrEF=0.83; 
HFpEF=0.83 mm Hg; p=0.63) and A-IVPD (No-HF=0.93; 
HFrEF=0.72; HFpEF=0.92 mm Hg; p=0.07) between 
the groups (table 2 and figure 2). In contrast, ER-IVPD 
was significantly different between the groups (ANOVA 
p=0.01), consistent with a more pronounced reversal of the 
early diastolic IVPD in HFpEF (−1.30 mm Hg) compared 
with the No-HF group (−0.78 mm Hg) and the HFrEF group 
(−0.75 mm Hg). After adjustment for age, sex, African 
American ethnicity, BMI, coronary artery disease, eGFR 
and medication use (adjusted model 1), these differences 
persisted (No-HF=−0.76; HFrEF=−0.85; HFpEF=−1.35 mm 
Hg; p=0.02). Similarly, these differences were present after 
further adjustment for Doppler-echocardiographic param-
eters (adjusted model 2: No-HF=−0.68; HFrEF=−0.99; 
HFpEF=−1.48 mm Hg; p=0.009) and LV structure (adjusted 
model 3: No-HF=−0.72; HFrEF=−0.87; HFpEF=−1.52 mm 
Hg; p=0.006).
systolic IVPds
In unadjusted analyses (table 2 and figure 2), there 
were significant differences between groups in S-IVPD 
(No-HF=1.7; HFrEF=1.41; HFpEF=1.99 mm Hg; 
p=0.01) and SR-IVPD (No-HF=−1.15; HFrEF=−0.90; 
HFpEF=−1.37 mm Hg; p=0.04), with more pronounced 
IVPDs in the HFpEF group compared with the HFrEF 
group. Between-group differences in SR-IVPD were 
also present after adjustment for general clinical 
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Figure 2 Comparison of IVPDs between groups for the 
unadjusted model. Computed parameters from diastole (left) 
and systole (right) are shown. Error bars represent 95% CIs. 
ANOVA, analysis of variance; HF, heart failure; HFrEF, HF with 
reduced ejection fraction; HFpEF, HF with preserved ejection 
fraction; IVPD, intraventricular pressure difference.
Figure 3 Selected IVPD parameters (ER and SR—wave 
peak pressures) with statistically significant differences 
between groups for adjusted models: (top) adjusted model 
1; (middle) adjusted model 2; (bottom) adjusted model 3. 
Computed parameters from diastole (left) and systole (right) 
are shown. Error bars represent 95% CIs. ANCOVA, analysis 
of covariance. HF, heart failure; HFrEF, HF with reduced 
ejection fraction; HFpEF, HF with preserved ejection fraction; 
IVPD, intraventricular pressure difference.characteristics and Doppler-echocardiographic param-
eters (adjusted model 2; table 2 and figure 3), but no 
significant differences in systolic IVPDs were found 
between the groups after further adjustment for LV struc-
ture (adjusted model 3; table 2 and figure 3).
Reproducibility and repeatability assessment
Higher reproducibility was demonstrated for diastolic 
E-IVPD and ER-IVPD parameters (r2≥0.70; SSE≤0.58; 
RPC≤0.55) in comparison with A-IVPD (r2=0.56; 
SSE=0.98; RPC=0.65) and systolic parameters (S-IVPD: 
r2=0.04; SSE=5.3; RPC=1.6; SR-IVPD: r2=0.47; SSE=1.3; 
RPC=0.76). This trend was maintained for the repeata-
bility assessment, although altogether higher indexes 
were found in this case (diastolic parameters: r2≥0.92; 
SSE≤0.21; RPC≤0.32; systolic parameters: r2≥0.71; 
SSE≤1.6; RPC≤0.87).
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Figure 4 Correlation coefficients between 
echocardiographic and MRI-based IVPDs parameters, 
showing correlation between IVPD (MRI-based) parameters: 
E-wave pressure peak (E-IVPD), E-wave reversal pressure 
peak (ER-IVPD), A-wave pressure peak (A-IVPD), S-wave 
pressure peak (S-IVPD) and S-wave reversal pressure peak 
(SR-IVPD); and echocardiographic parameters: peak E-wave 
and A-wave velocities by Doppler (E and A-Vel), deceleration 
time (Dec-time), e’ velocity (lateral (e’-lat) and septal (e’-sep)) 
and E/e’. IVPD, intraventricular pressure difference.
echocardiographic/MRI correlation assessment
There were only weak correlations between standard 
Doppler-echocardiographic parameters and IVPD param-
eters (R<0.20 for all, except for the correlation between 
ER-IVPD and peak A-wave velocity (R=−0.30)). Correla-
tion coefficients between standard Doppler-echocardio-
graphic indices of diastolic function and IVPD parame-
ters are presented in figure 4.
dIsCussIOn
We compared diastolic and systolic IVPDs between 
subjects with HFrEF, HFpEF or No-HF. We found physi-
ologically expected patterns of IVPD in all three groups, 
with significant differences in diastolic IVPDs. Specifically, 
subjects with HFpEF exhibited more pronounced reversal 
peak of early diastolic IVPDs, which was independent of 
clinical parameters, echocardiographic parameters of 
LV filling, and LV structure assessed by MRI. Subjects 
with HFrEF demonstrated a non-significant trend of 
increasing E-IVPD and decreasing A-IVPD, S-IVPD and 
SR-IVPD. Our findings suggest distinct patterns of systolic 
and diastolic IVPDs and differences in the nature of both 
diastolic and systolic dysfunction between HF subtypes. 
IVPD parameters demonstrated only weak correlations 
with standard Doppler-echocardiographic parameters.
Previous studies have shown that, despite being small 
in magnitude, IVPDs have a significant role in effi-
cient filling and emptying of the LV and could be used 
to characterise cardiac performance.8 20 However, the 
assessment and interpretation of intraventricular pres-
sure gradients in clinical practice remains complicated 
by its dependency on a large number of factors and inter-
actions.10 21 Furthermore, flow occurs in multiple and 
rapidly changing directions, forming complex vortex 
patterns.10 20 The complexity of intraventricular flow and 
technical limitations of ultrasound imaging, the standard 
method in cardiovascular assessment, make it difficult to 
relate intraventricular flow patterns and derived IVPDs to 
LV myocardial function in a quantitative manner.10 20 21
The increasing availability of cardiovascular MRI has 
made it an advantageous alternative from a technical 
point of view due to its high image quality, reproduc-
ibility, repeatability, plane of view flexibility, sufficient 
spatial and temporal resolution and reduced operator 
dependency. Furthermore, MRI-based IVPD calculations 
allow for a more flexible definition and alignment of 
the operator’s ‘scan line’, which could be relevant when 
the blood flow exhibits a curved trajectory.17 Addition-
ally, two-dimensional-velocity information from phase 
contrast MRI improves the accuracy of IVPDs even if the 
temporal resolution, a critical parameter to calculate 
IVPDs,22 is lower in comparison with ultrasound. In fact, 
Thompson and McVeigh13 reported that a minimum 
temporal resolution of 44 ms may avoid significant 
underestimation of the local acceleration contribution 
to the total intracardiac pressure differences. Previously, 
making use of computational fluid dynamics simula-
tions, we assessed the impact of temporal resolution in 
IVPD calculations, showing that the temporal resolution 
of phase contrast MRI is, at least in theory, sufficient to 
resolve IVPDs. Furthermore, we also showed that IVPDs 
estimated by a one-dimensional method as colour-Dop-
pler ultrasound are larger in magnitude than when 
the two-dimensional velocity information was used, 
but the estimates based on two-dimensional velocity 
information are more accurate, especially in extreme 
scan line misalignments,23 which could be particularly 
sensible after mid and late diastole due to formation 
of vortices.8 14 We speculate that this explains, at least 
partly, some of the difference between values reported 
here and in other studies.9 15–17
There were no significant differences in E-IVPD and 
A-IVPD between the groups. This may be a consequence 
of early filling pseudonormalisation due to greater filling 
pressures. Additionally, in HFpEF patients, pronounced 
diastolic abnormalities can often be elicited only during 
physiological perturbations, such as exercise or dobutamine 
infusions,24–26 as subjects with HFpEF exhaust their reserve 
to preserve the diastolic suction force at rest, limiting their 
ability for adaptation to stress.24 25 Nonetheless, our results 
demonstrate that HFpEF is associated with a greater magni-
tude of the ER-IVPD. Although, the slope of mitral inflow 
deceleration temporally coincides with ER-IVPD, it is inter-
esting to note that we did not find significant differences 
in the deceleration time between the groups, and that 
ER-IVPD was not strongly related to the deceleration time. 
G
eneeskunde - P8 / 1e Verd. Protected by copyright.
 o
n
 D
ecem
ber 24, 2019 at Biom
edische Bibliotheek Fac
http://openheart.bmj.com/
O
pen Heart: first published as 10.1136/openhrt-2019-001088 on 9 O
ctober 2019. Downloaded from
 
Open Heart
8 Londono-Hoyos F, et al. Open Heart 2019;6:e001088. doi:10.1136/openhrt-2019-001088
Therefore, our data suggests that ER-IVPD may be a more 
sensitive marker of diastolic function in HFpEF.
We also examined systolic IVPDs. A typical biphasic IVPD 
pattern was observed in systole, with a positive peak imme-
diately followed by a negative one. HFrEF individuals exhib-
ited lower values, whereas the HFpEF group presented an 
overall higher total magnitude of S-IVPD and SR-IVPD, 
suggesting differences in systolic flow dynamics between 
groups. These differences could be related to the unsteady 
nature of ejective flow, abnormalities in chamber geometry, 
and/or the sequence of regional contraction.20
Our reproducibility and repeatability assessments 
suggest a general adequate inter and intra-operator vari-
ability for early diastolic IVPD parameters. Reproduc-
ibility and repeatability were lower for A-IVPD, probably 
due to a more complex flow after mid and late diastole.8 14 
Systolic parameters evidenced a need to refine the stan-
dardisation of the method, particularly for S-IVPD. 
The overall correlation between IVPD parameters and 
echocardiographic indexes was weak or non-existent. 
In fact, previous publications have pointed out a weak 
correlation between Doppler echocardiographic esti-
mates of LV filling pressure with invasive filling pressure 
measurements and the necessity to include further anal-
ysis of non-invasive measures.27 28 In contrast, echocar-
diographic16 17 and MRI13 based IVPD parameters have 
shown good agreement against invasive intraventricular 
measurements, adding potentially relevant information 
for cardiovascular assessments.
The reported data should be interpreted considering 
the strengths and limitations of the study. Strengths of 
this study are the inclusion of patients with HFrEF and 
HFpEF, and the assessment of IVPDs with phase-contrast 
MRI, which overcomes a number of assumptions made 
with colour M-mode echocardiography and allows for a 
more consistent interrogation of intraventricular flow. 
Our study also has limitations. We did not perform inva-
sive catheter-based measures of distensibility which would 
have been unfeasible in the absence of a clinical indica-
tion for LV catheterisation. From a technical point of 
view, the MRI acquisition requires relative long breath-
holds (~20 s) and has limited temporal and through 
plane spatial resolution, while the processing could 
be affected by the image alignment and assumptions 
made about the nature of flow from the three cham-
bers view. On computation of the IVPDs, viscous forces 
are neglected and it is assumed that inflow and outflow 
is laminar.9 17 25 On average, our HFpEF subjects did not 
have marked left atrial enlargement, suggesting the pres-
ence of mild HFpEF. This may have led to underestima-
tions of true underlying differences. Our population was 
a clinical sample referred for a cardiac MRI study, which 
may not fully represent population-based trends. More-
over, complementary myocardial mechanic studies could 
be included to improve the analysis.29
In conclusion, we demonstrated the feasibility to assess 
IVPDs throughout the cardiac cycle using phase-contrast 
MRI and compared IVPDs between subjects without HF 
and subjects with HFrEF and HFpEF. Our findings suggest 
distinct patterns of diastolic IVPDs in HFpEF, implying 
differences in the nature of diastolic dysfunction between 
the HF subtypes. Further research is warranted to exploit 
MRI analysis thoroughly to assess the significance of these 
novel indices regarding risk stratification and response to 
therapy.
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